John Sarantopoulos
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Research top 5%
Papers in
- Oncology 23
- Cancer Treatment and Pharmacology 8
- HER2/EGFR in Cancer Research 5
- Pancreatic and Hepatic Oncology Research 5
-
- Microtubule and mitosis dynamics 6
- Co-authors
- Devalingam Mahalingam (21 shared papers)Alain C. Mita (17 shared papers)Monica M Mita (14 shared papers)Anthony W. Tolcher (9 shared papers)Tyler Jay Curiel (3 shared papers)Francis Joseph Giles (4 shared papers)Chia‐Chi Lin (2 shared papers)Jordi A. Rodon (4 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (17 papers)Clinical Cancer Research (12 papers)Investigational New Drugs (5 papers)Annals of Oncology (4 papers)Molecular Cancer Therapeutics (3 papers)
- Partner nations
- United StatesSwitzerlandJapan
In The Last Decade
John Sarantopoulos
70 papers receiving 2.9k citations
John Sarantopoulos's Hit Papers
Peers
Comparison fields: 5 of 108
- Oncology 957
- Cancer Research 288
- Molecular Biology 1.3k
- Physiology 83
- Genetics 181
Countries citing papers authored by John Sarantopoulos
This map shows the geographic impact of John Sarantopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sarantopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sarantopoulos more than expected).
Fields of papers citing papers by John Sarantopoulos
This network shows the impact of papers produced by John Sarantopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sarantopoulos. The network helps show where John Sarantopoulos may publish in the future.
Co-authors
The 25 scholars most cited alongside John Sarantopoulos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 72 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors Hit paper breakdown → | 2021 | 284 |
| 2 | 2014 | 257 | |
| 3 | 2009 | 251 | |
| 4 | 2014 | 194 | |
| 5 | 2013 | 160 | |
| 6 | 2011 | 154 | |
| 7 | 2015 | 147 | |
| 8 | 2010 | 90 | |
| 9 | 2010 | 90 | |
| 10 | 2017 | 78 | |
| 11 | 2012 | 76 | |
| 12 | 2019 | 75 | |
| 13 | 2016 | 70 | |
| 14 | 2012 | 65 | |
| 15 | 2020 | 58 | |
| 16 | 2011 | 51 | |
| 17 | 2017 | 48 | |
| 18 | 2019 | 48 | |
| 19 | 2012 | 42 | |
| 20 | 2014 | 42 |
About John Sarantopoulos
John Sarantopoulos is a scholar working on Oncology, Cell Biology, Pulmonary and Respiratory Medicine, Molecular Biology and Hepatology, having authored 72 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Microtubule and mitosis dynamics (6 papers), HER2/EGFR in Cancer Research (5 papers), Pancreatic and Hepatic Oncology Research (5 papers), Lung Cancer Treatments and Mutations (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Histone Deacetylase Inhibitors Research (3 papers) and Cancer Mechanisms and Therapy (3 papers). The work is most often cited by research in Oncology (957 citations), Cancer Research (288 citations), Molecular Biology (1.3k citations), Physiology (83 citations) and Genetics (181 citations). John Sarantopoulos has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Devalingam Mahalingam, Alain C. Mita, Monica M Mita, Anthony W. Tolcher, Tyler Jay Curiel, Francis Joseph Giles, Chia‐Chi Lin, Jordi A. Rodon, Kamalesh Kumar Sankhala and Andrew Jacob Brenner. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Clinical Cancer Research, Investigational New Drugs, Annals of Oncology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.